Expansion in the world
Since the early 1980s, we have started to build our network in Asia, with a steady growth of business throughout the territory: Hong Kong (1981), Singapore (1987), Malaysia (1988), Thailand (1992) and more recently Vietnam and Myanmar.
Our history in South America began in 1989 in Brazil, rapidly spreading to Argentina in 1992. Today, these countries are home to two of our production facilities that manufacture a wide range of therapeutic products for rheumatology, pain management, infectious diseases and neurology. Both sites comply with international GMP standards. We are now present in more than 9 countries in this region.
Pioneers in hyaluronic acid-based therapeutic interventions.
We have been pioneers in the development of medical devices based on sodium hyaluronate with biofermentative origin for intra-articular use and for the treatment of dry eye. With more than 20 years of experience, all of our products comply with the highest international standards and guarantee patient satisfaction and safety.
Launch of OSTENIL® in 1998
TRB Chemedica has set new standards for the treatment of osteoarthritis (OA) with OSTENIL®, our formulation of hyaluronic acid for intra-articular use. Celebrating 20 years of optimal efficacy and safety, OSTENIL® has been shown to be highly effective in providing symptomatic relief to patients suffering from symptomatic OA. 1-5 The OSTENIL® products were the first hyaluronic acid formulations of fermentative origin approved for intra-articular injection in all synovial joints.
London 2012 Olympics
We were honored to have three of our products listed on the official formulary for the London 2012 Olympic Games. OSTENIL®, OSTENIL® Plus and OSTENIL® MINI were the only intra-articular injections of hyaluronic acid included in the "Pharmacy Guide for the London 2012 Olympics ".